MedTrace Logo

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

NCT05813795 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 664

Last updated 2025-04-30

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

Conditions

Interventions

DRUG

Ecnoglutide Low Dosage

Subcutaneous Injection

DRUG

Ecnoglutide Medium Dosage

Subcutaneous Injection

DRUG

Ecnoglutide High Dosage

Subcutaneous Injection

DRUG

Placebo

Subcutaneous Injection with matched volume

Sponsors & Collaborators

  • Hangzhou Sciwind Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Linong Ji, Dr · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-05
Primary Completion
2024-06-20
Completion
2024-10-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813795 on ClinicalTrials.gov